Philippine News Agency
3 million doses of Sputnik V coming after EUA grant
The Food and Drug Administration (FDA) has granted an emergency use authorization (EUA) for Russia's Sputnik V vaccine against COVID-19.
Interim data from ongoing phase three trials, published in The Lancet, indicate an overall efficacy rate of 91.6% in preventing COVID-19 across all age groups 18 and older.
The Sputnik V vaccine is administered as two intramuscular injections of 0.5 ml each, given 21 days apart.
Reported adverse events from the vaccine are mostly mild and transient, comparable to common vaccine reactions.
Following the EUA grant, the Philippine government plans to order approximately three million doses of the Sputnik V vaccine, with initial deliveries expected in April or May.
Negotiations are also underway to allow local government units and private companies to procure the Sputnik V vaccine.
Over 20 to 30 countries are reportedly using the Sputnik V vaccine.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Philippine FDA has granted an emergency use authorization (EUA) for Russia's Sputnik V vaccine, making it the fourth vaccine to receive regulatory approval in the country.
Read more →
The FDA has canceled its planned inspection trip to Russia because the Gamaleya Institute has already submitted the necessary documents for the Sputnik V vaccine's emergency use authorization (EUA).
Read more →
Government agencies, including the Department of Health (DOH) and the Food and Drug Administration (FDA), are warning the public against the unauthorized selling of COVID-19 vaccines.
Read more →